Acurx Pharmaceuticals, Inc. (ACXP) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of antibiotics targeting Gram-positive bacteria. The company's lead product candidate is ibezapolstat, designed to treat Clostridioides difficile infections (CDI). The company has not generated any revenue since inception and relies on equity financing to fund operations.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(4.12) million | $(8.50) million | $(6.35) million |
| Loss Per Share (Basic/Diluted) | $(0.26) | $(0.54) | $(0.53) |
| Cash and Equivalents (End of Period) | $6.36 million (as of June 30, 2024) | ||
| Working Capital | $3.43 million (as of June 30, 2024) | ||
| Net Cash Used in Operating Activities | $(5.94) million (YTD 2024) | ||
| Net Cash Provided by Financing Activities | $4.83 million (YTD 2024) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by 34% year-over-year for the six months ended June 30, 2024, rising from $6.35 million to $8.50 million.
- Research & Development (R&D): R&D expenses increased by 23% ($0.63 million) primarily due to a $0.8 million increase in manufacturing-related costs, partially offset by a decrease in consulting fees.
- General & Administrative (G&A): G&A expenses increased by 42% ($1.52 million), driven by a $1.0 million increase in professional fees and a $0.4 million increase in share-based compensation costs.
- Liquidity: Cash balances decreased by approximately $1.1 million during the first half of 2024, compared to a slight increase of $34,000 in the same period in 2023.
Guidance, Outlook, and Risks
- Regulatory Progress: The company held a successful End-of-Phase 2 meeting with the FDA in April 2024, confirming readiness for Phase 3 clinical trials for ibezapolstat. An international Phase 3 program is being planned, and a manufacturing meeting with the FDA is anticipated in Q4 2024.
- Capital Resources: Management states that current cash resources ($6.4 million) are not sufficient to meet anticipated cash requirements for at least 12 months from the issuance date. The company expects to continue incurring losses and will need additional equity financing or grant funding.
- Financing Activity: The company utilized its At-the-Market (ATM) offering program, raising approximately $4.6 million in net proceeds during the six months ended June 30, 2024. Approximately $9.6 million remains available under the ATM facility.
- Going Concern: The filing notes substantial doubt about the company's ability to continue as a going concern without additional financing. There is no assurance that funding will be available on acceptable terms.
- Risks: Key risks include the failure of Phase 3 trials, inability to secure regulatory approval, dependence on third-party manufacturers, and potential dilution from future equity offerings.
Investor Verification Checklist
- Verify the timeline and budget for the upcoming international Phase 3 clinical trials for ibezapolstat.
- Confirm the status of the FDA manufacturing meeting scheduled for Q4 2024 and any potential delays.
- Assess the remaining capacity of the ATM program ($9.6 million) and the company's strategy for raising additional capital beyond this facility.
- Review the concentration of R&D spending on specific vendors (two vendors accounted for 35% and 75% of R&D spend in Q2 2024 and 2023, respectively).
- Monitor the burn rate relative to the $6.4 million cash balance to determine the runway for operations.